×
  • Category
  • Type
  • Advanced

P3.1 The enduring dilemma of 20 million unvaccinated children: Equity and access solutions in IA2030

KN3 Research for Equity

P1.1 Research during outbreak response: from Ebola to the COVID-19 pandemic

W5.4 Improved vaccines: Novel oral polio vaccine (OPV)

W9.1 Building and Sustaining Uptake: Summary of the latest evidence and open research questions

P2.2 Update on progress in tuberculosis vaccine development

Briefing on single-dose HPV vaccination evidence

KN1 Vaccinology in the context of pandemic preparedness: The COVID-19 experience

W7.1 Protection of newborn infants through vaccination

COVID-19 Vaccine Label: User Evaluation

W6.2 Vaccine development to access: Is there a role for earlier policy consideration?

W5.1 Salmonella typhi vaccines, development and deployment

P3.2 Impact of COVID-19 on coverage and equity

W5.2 Schistosomiasis vaccines, development and role in elimination

W4.1 Controlled human malaria infection — tool for accelerating vaccine development

P1.2 Rapid Response Platforms for COVID-19 Vaccine

P2.1 Current status and future prospects for human immunodeficiency virus (HIV) vaccines

W2.4 Universal Influenza Vaccines

W3.3 Considerations for mass deployment of innovative vaccines in low- and middle-income country immunization programs

W2.1 Nucleic acid vaccines: Is it all done?